Global Hepatic Encephalopathy Market - Regional Analysis
Among all regions, North America is expected to dominate the global market over the forecast period. This is attributed to North America holding a 34.8% market share and due to presence of major players such as ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V, Lupin Limited., Kaleido Biosciences., and others are contributing for development of Hepatic Encephalopathy market.
The European region is expected to be second dominating region over the forecast period, due to increase in cirrhosis and liver failure. For instance, September, 2021 according to the National Center of Biotechnology and Information and clinical liver disease (CLD), cirrhosis is a leading cause of mortality and morbidity across the world. It is the 11th leading cause of death and 15th leading cause of morbidity, accounting for 2.2% of deaths and 1.5% of disability-adjusted life years worldwide in 2016. 1 CLD caused 1.32 million deaths, approximately two-thirds among men and one-third among women.
Hepatic Encephalopathy Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients